AstraZeneca PLC
15 March 2005
Dealing by Directors
Companies Act 1985 Sections 324/329
We hereby inform you that on 14 March 2005, Sir Tom McKillop, a Director of the
Company, exercised an option over 24,513 AstraZeneca PLC USD0.25 Ordinary Shares
at an option price of 891 pence per share. The option was granted to Sir Tom
McKillop in March 1995 under the Company's 1994 Executive Share Option Scheme
and is due to expire on 26 March 2005 if not exercised before then.
As a result of this exercise, Sir Tom McKillop holds options over 547,351
Ordinary Shares of AstraZeneca PLC.
We also inform you that on 14 March 2005, Sir Tom McKillop sold 10,180 of the
shares acquired from the exercise at an average price of 2176 pence per share in
order to meet the cost of exercising the option.
Following these transactions, Sir Tom McKillop has increased his holding in the
Company by 14,333 shares to 92,168 shares, which represents approximately 0.006%
of the issued ordinary capital of the Company.
G H R Musker
Company Secretary
15 March 2005
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.